Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
暂无分享，去创建一个
J. Issa | Y. Oki | Z. Estrov | H. Kantarjian | G. Garcia-Manero | J. Cortes | Xuelin Huang | F. Ravandi | C. Bueso-Ramos | S. O'brien | F. Giles | W. Wierda | S. Faderl | A. Ferrajoli | J. Shan | H. Saba | Jan Davis | C. Bueso‐Ramos